Sign in

Hospital Acquired Infections Therapeutic Market Growth, Industry Analysis, Business Opportunities and Latest Innovations

Hospital Acquired Infections Therapeutic Market Growth, Industry Analysis, Business Opportunities and Latest Innovations

The hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research. The report “Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections. The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.

In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck’s Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older. This is expected to drive the market for hospital acquired infections therapeutic.

Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed. As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.

Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request-for-sample

Asia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period. This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.

Hospital Acquired Infections Therapeutic Market

For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China. Thus, with increased hospital admissions, the market demand for hospital acquired infections therapeutics is bound to rise. Market participants such as Merck, Abbott Laboratories, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AbbVie Inc., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Limited and Allergan Plc.

Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request-for-discount-pricing

Hospital Acquired Infections Therapeutic, Drug Class Outlook (Revenue – USD Million, 2016 – 2028)

  • Antibacterial Drugs
    • Cell Wall Synthesis Inhibitors
    • Protein Synthesis Inhibitors
    • Others
  • Antiviral Drugs
  • Antifungal Drugs

Hospital Acquired Infections Therapeutic, Infection Type Outlook (Revenue – USD Million, 2016 – 2028)

  • Urinary Tract Infections
  • Ventilator-associated Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Other Hospital Infections

Buy Now @ https://www.polarismarketresearch.com/checkouts/8331

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Contact Us:

Polaris Market Research

Phone: 1–646–568–9980

Email: [email protected]

Web: www.polarismarketresearch.com

Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more